Rosett, Heather A. http://orcid.org/0000-0002-4131-8563
Locke, Susan C.
Wolf, Steven P.
Herring, Kris W.
Samsa, Gregory P.
Troy, Jesse D.
LeBlanc, Thomas W.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR002553)
National Cancer Institute (P30CA014236)
Article History
Received: 4 September 2019
Accepted: 2 February 2020
First Online: 10 February 2020
Compliance with ethical standards
:
: The Duke BERD Methods Core’s support of this project was made possible (in part) by Grant Number UL1TR002553 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCATS or NIH. This work was also supported in part by grant number P30CA014236 from the National Cancer Institute at the NIH.
: Heather Rosett: None to disclose.Susan C. Locke:Consulting - Robin Care, Inc.Consulting - Predigen, Inc.Steven P. Wolf: None to disclose.Kris W. Herring: None to disclose.Gregory P. Samsa: None to disclose.Jesse D. Troy:Honorarium for serving on DSMB for Ghbamida Cell.Consulting services to The EMMES Corporation, the Community Data Roundtable, AegisCN, Cohortias International.Thomas W. LeBlanc:I am currently, or have recently been, a consultant for AstraZeneca, CareVive, Flatiron, Helsinn, Otsuka, Pfizer, and Seattle Genetics. I have served on recent advisory boards for AbbVie, Agios, Amgen, Daiichi-Sankyo, Heron, Medtronic, and Otsuka. I have received honoraria from Agios and Celgene, for non-branded speaking engagements. I have received recent research funding from the American Cancer Society, AstraZeneca, Duke University, Jazz Pharmaceuticals, the National Institute of Nursing Research / National Institutes of Health, and Seattle Genetics.
: We have full control of all primary data dn agree to allow the journal to review these data if requested.